Asia-Pacific monoclonal antibodies market is estimated to grow at a CAGR of 8.9% during the forecast period. Significant rise in the incidences of cancer and infectious diseases and increasing approvals of biosimilars are primarily encouraging the market growth. The rising number of approvals for monoclonal antibodies biosimilars has been reported in the region owing to the increasing government focus towards improving access to care for patients. For instance, in October 2020, Cadila Pharmaceuticals introduced two similar biologics in the Indian market. This includes Cadalimab, a similar biologic of the auto-immune treatment adalimumab, and NuPTH, a teriparatide similar biologic. Cadila has revealed four new products in India since July 2020. 

Visit for Global Monoclonal Antibodies Market Report at: https://www.omrglobal.com/industry-reports/monoclonal-antibodies-market

Adalimumab is a monoclonal antibody therapy for inflammatory diseases which include several types of arthritis, psoriasis, and inflammatory bowel disease (IBD). Adalimumab was the first human monoclonal antibody treatment approved by the US FDA which is sold with the brand name Humira since 2003. A biosimilar of adalimumab is sold as Cadalimab which is available in a form of a pre-filled syringe to facilitate ease of use. This biosimilar has been demonstrated to be effective to treat rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, psoriasis, and ankylosing spondylitis. It is available in a 40 mg/0.8 mL injectable dose. The increasing launches of biosimilars are offering hope for patients with cancer, auto-immune diseases, infectious diseases, and others, to receive affordable treatment. This, in turn, is providing an enormous scope for market growth.

Asia-Pacific monoclonal antibodies market is segmented based on source and application. Based on the source, the market is classified into murine, chimeric, human, and humanized. Based on the application, the market is classified into cancer, infectious diseases, auto-immune diseases, inflammatory diseases, and others. In 2019, cancer held the largest share in the market owing to the rising cancer incidences and increasing demand for targeted and immunotherapies for cancer treatment in the region. As per the World Health Organization (WHO), the number of new cancer incidences reported in China was nearly 4.3 million in 2018. Additionally, the number of new cancer incidences reported in India was nearly 1.1 million in 2018. This results in an emerging demand for monoclonal antibody therapies that serve as targeted and immunotherapy to find and attack cancer cells. 

Some key players in the market include Biocon Ltd., Amgen Inc., F. Hoffman La-Roche AG, Pfizer Inc., and Mylan N.V. Product launches and partnerships and collaborations are regarded as some potential strategies implemented by the market players to increase their position in the marketplace. For instance, in July 2020, Cadila Pharmaceuticals Ltd. declared the introduction of biosimilar Rituximab in India. It is indicated for the treatment of rheumatoid arthritis and blood cancer launched within the brand name Ritucad. It is used to treat Non-Hodgkin’s lymphoma (a type of blood-related cancer). According to the company, over 28,000 new cases of Lymphoma are reported each year in India. This launch will increase the accessibility of cancer treatment in the country. 

Research Methodology

The market study of the Asia-Pacific monoclonal antibodies market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Asia-Pacific Monoclonal Antibodies Market Research and Analysis by Source
2. Asia-Pacific Monoclonal Antibodies Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the Asia-Pacific monoclonal antibodies market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the Asia-Pacific monoclonal antibodies market.
• Insights about market determinants which are stimulating the Asia-Pacific monoclonal antibodies market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.